Trial | NCT00162851  Report issue

Title

Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Indication/Condition

    B-CLL

  • Study Participants

    20
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).
Study Started
Apr 30
2003
Study Completion
Jul 31
2006
Last Update
Jul 25
2007
Estimate

Drug alemtuzumab

Criteria 

Inclusion Criteria:

B-CLL that has failed fludarabine

Exclusion Criteria:

Performance status grade 3
No Results Posted